Skip to main content

Table 1 Baseline patient demographics and characteristics according to treatment group

From: Efficacy and safety of HIP1601 (dual delayed-release esomeprazole) 40 mg in erosive esophagitis compared to HGP1705 (delayed-release esomeprazole) 40 mg: a multicenter, randomized, double-blind, non-inferiority study

 

HIP1601

(n = 103)

HGP1705

(n = 100)

P-value

Age (mean ± SD), year

52.5 ± 13.5

51.3 ± 13.9

0.499

Male

73 (70.9%)

73 (73.0%)

0.736

Height (mean ± SD), cm

166.8 ± 8.6

166.1 ± 8.5

0.572

Weight (mean ± SD), kg

71.3 ± 12.5

70.3 ± 13.0

0.333

Smoker

21 (20.4%)

23 (23.0%)

0.652

Alcohol

60 (58.3%)

62 (62.0%)

0.586

LA Classification

  

0.369

 Grade A

70 (68.0%)

63 (63.0%)

 

 Grade B

27 (26.2%)

34 (34.0%)

 

 Grade C

6 (5.8%)

3 (3.0%)

 

 Grade D

0 (0%)

0 (0%)

 

GERD-related symptoms

   

 Heartburn

86 (83.5%)

81 (81.0%)

0.585

 Acid regurgitation

83 (80.6%)

81 (81.0%)

0.563

 Dysphagia

12 (11.7%)

20 (20%)

0.207

 Epigastric pain

42 (40.8%)

46 (46.0%)

0.878

 Heartburn (night)

42 (40.8%)

47 (47.0%)

0.372

 Acid regurgitation (night)

38 (36.9%)

41 (41.0%)

0.549

 Dysphagia (night)

3 (2.9%)

11 (11.0%)

0.023

 Epigastric pain (night)

24 (23.3%)

21 (21.0%)

0.693

H. pylori infection

19 (18.5)

16 (16.0)

0.645

Treatment compliance (mean ± SD)

97.2 ± 5.5

98.1 ± 4.7

0.220

Number of rescue medication administered (mean ± SD)

7.8 ± 8.9

9.3 ± 12.0

0.917

  1. GERD, Gastroesophageal reflux disease; LA, Los Angeles; SD, standard deviation